Adcy9 Protein — Adenylate Cyclase 9 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Adenylate Cyclase 9 |
|---|
| Protein Name | ADCY9 |
| Gene | ADCY9 |
| UniProt ID | O60344 |
| PDB Structure | 6X3V, 6UOV |
| Molecular Weight | 135 kDa |
| Subcellular Localization | Plasma membrane |
| Brain Expression | Cortex, hippocampus, cerebellum, olfactory bulb |
ADCY9 (Adenylate Cyclase 9) is a membrane-bound enzyme that catalyzes the conversion of ATP to cyclic AMP (cAMP). It is one of nine adenylate cyclase isoforms in humans, each with distinct tissue distribution and regulatory properties. ADCY9 is particularly abundant in the brain and plays important roles in neuronal signaling, synaptic plasticity, and neuroprotection.
ADCY9 has a characteristic adenylate cyclase architecture:
- Two six-transmembrane domain clusters (M1 and M2)
- Two cytoplasmic catalytic domains (C1 and C2)
- G-protein (Gαs) binding and activation site
- Forskolin binding site for direct activation
- Regulatory phosphorylation sites
ADCY9 produces cAMP in response to:
- Gαs-coupled receptor activation (e.g., dopamine D1 receptors, adenosine A2 receptors)
- Forskolin direct activation
- β-adrenergic receptor stimulation
- Synaptic plasticity: cAMP regulates AMPA receptor trafficking and LTP
- Learning and memory: Hippocampal cAMP signaling essential for memory formation
- Reward processing: Dopamine-cAMP pathway in striatal medium spiny neurons
- Circadian rhythm: cAMP oscillations in suprachiasmatic nucleus
ADCY9 is widely expressed:
- Cerebral cortex (layers II-III, V)
- Hippocampus (CA1, CA3, dentate gyrus)
- Cerebellum (Purkinje cells)
- Olfactory bulb
- Striatum
- Synaptic dysfunction: ADCY9 activity affects amyloid-beta-induced synaptic impairment[^1]
- cAMP dysregulation: Altered cAMP signaling contributes to cognitive decline
- Therapeutic targeting: Adenylate cyclase modulators under investigation
- Dopaminergic signaling: ADCY9 mediates D1 receptor cAMP production[^2]
- L-DOPA-induced dyskinesia: cAMP pathway overactivation contributes to dyskinesias
- Neuroprotection: Modulating ADCY9 may protect dopaminergic neurons
- cAMP signaling deficits: Reduced adenylate cyclase activity in HD models[^3]
- Therapeutic potential: Enhancing cAMP signaling may improve neuronal function
¶ Stroke and Ischemia
- Ischemic preconditioning: ADCY9 activation provides neuroprotection
- cAMP-mediated survival: PKA-dependent pathways protect neurons
ADCY9 is a potential therapeutic target:
- Forskolin: Direct adenylate cyclase activator, studied for cognitive enhancement
- Colforsin: Potent forskolin derivative
- GPCR modulators: Target upstream receptors (D1, A2A, β-adrenergic)
- PDE inhibitors: Prevent cAMP degradation to enhance signaling
- Selectivity across isoforms is challenging
- Brain-penetrant modulators needed
- Combination approaches with PDE inhibitors promising
The study of Adcy9 Protein — Adenylate Cyclase 9 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- ADCY9 and amyloid-beta synaptic toxicity
- Adenylate cyclase in dopaminergic signaling and Parkinson's disease
- cAMP signaling alterations in Huntington's disease
- Adenylate cyclase isoforms in the brain
- Forskolin and cAMP in neuroprotection